Human papillomavirus type 16 E5 protein (HPV16 E5) upregulates ligand-mediated activation of the epidermal growth factor receptor (EGFR) in transfected human keratinocytes. HPV16 E5 binds to the 16 kDa proteolipid (subunit c) of the vacuolar H + -ATPase (16K), responsible for endosomal acidi®cation, and this binding has been suggested to be responsible for increased recycling of the EGFRs. Using mutant deletions we show here that amino acids 54 ± 78, but not 79 ± 83 are necessary for binding to the 16K proteolipid. EGF treatment of cells expressing wild type or mutants of the E5 protein show that deletion of the last carboxy terminal 5 amino acids results in loss of E5-mediated EGFR overactivation. Thus, our results show that the binding capacity of HPV16 E5 to 16K can be dissociated from the eect of the viral protein on EGFR activation.
Introduction
Human papillomaviruses (HPVs) have been associated with tumoral growth. For example, HPV type 16 (HPV16) has been found in more than 70% of well developed human cervical cancers (zur Hausen and Schneider, 1987; zur Hausen, 1991) . Two virus-encoded proteins, E6 and E7, seem to be mainly responsible for the transforming properties of this virus (DuÈ rst et al., 1987; Matlashewski et al., 1987; Pirisi et al., 1987) . Another viral protein, E5, has been found to be weakly oncogenic and to increase E7-mediated cell transformation (Leptak et al., 1991; Leechanachai et al., 1992; Pim et al., 1992; Bouvard et al., 1994; Faulkner-Valle and Banks, 1995) . HPV16 E5 is an hydrophobic membrane protein, 83 amino acids long, located mainly at the endosomal membranes, Golgi apparatus and, to a lesser extent, the plasma membranes (Burkhardt et al., 1989; Conrad et al., 1993) . Hydropatic analysis of the protein shows the existence of three well de®ned hydrophobic regions, of which the ®rst one is the longest (Bubb et al., 1988) . No secondary modi®cation of the protein is known so far, and in vitro transcription-translation experiments show the protein is rapidly incorporated into microsomal membranes.
In contrast to bovine papillomavirus type 1 (BPV1), where E5 is the main oncogene, little is known about the biological activity of HPV16 E5. In cervical intraepithelial neoplasias lesions and carcinomas, abundant mRNA sequences containing the E5 ORF have been found (Stoler et al., 1992; Kell et al., 1994) . However, the signi®cance of this ®nding is unknown, since E5 is transcribed as part of a multicistronic RNA and no antibodies speci®c for HPV16 E5 exist to analyse the protein content in these lesions. In addition, in well developed carcinomas, E5 has been found to be frequently deleted upon incorporation of the viral DNA into the host genome, suggesting that E5 is not necessary to maintain the malignant state (Bauer-Hofmann et al., 1996) .
It has been shown that in HPV16 E5-transfected mouse ®broblasts, E5 increases cellular growth and this growth is accelerated by addition of epidermal growth factor (EGF) but not platelet derived growth factor (PDGF; Leechanachai et al., 1992; Pim et al., 1992; Straight et al., 1993) . The molecular basis for this eect is unknown, although E5 has been shown to bind the EGF receptor (EGFR) when both proteins are overexpressed in COS cells by transfection (Hwang et al., 1995) . Moreover, in human keratinocytes, the target cells for the virus, long-term treatment with EGF results in an E5-mediated increase in the number of EGFRs at the cell surface (Straight et al., 1993) . BPV1 E5 may act in a similar manner as this transforming protein binds to the PDGF receptor (PDGFR) and BPV1 E5 expressing cells respond to addition of PDGF (Petti et al., 1991; Petti and DiMaio, 1992) .
Both HPV16 E5 and BPV1 E5 bind to the highly conserved, 16 kDa subunit c proteolipid (16K proteolipid) of the vacuolar H + -ATPase (V-ATPase; Goldstein and Schlegel, 1990; Goldstein et al., 1991; Conrad et al., 1993) . The V-ATPase is a universal proton pump of eukaryocytes and is responsible for acidifying membrane bound organelles (e.g. Golgi, endosomes, lysosomes, and certain secretory vesicles) (see Finbow and Harrison 1997 for review) . Thus, it has been postulated that binding of these two viral transforming proteins to the 16K proteolipid would inhibit endosomal acidi®cation leading to an increase in receptor recyling to the plasma membrane (Straight et al., 1993 (Straight et al., , 1995 . The eect of this mechanism would therefore be an increased number of receptors at the cell surface giving rise to increased signalling in E5-expressing cells (Leechanachai et al., 1992; Pim et al., 1992) . BPV1 E5 is also known to increase the pH of Golgi which again Oncogene (2000) 19, 3727 ± 3732 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: A Alonso,is thought to be by its binding to the 16K proteolipid (Schapiro et al., 2000) .
Nevertheless, disturbance of the V-ATPase cannot be the only mechanism involved in the process for at least HPV16 E5 since reagents which lower the pH of the endosomal milieu do not aect EGFR recycling (Straight et al., 1995) . Further, it is dicult to explain why only EGFR would be aected by the change in endosomal pH and not other tyrosine kinase receptors that take the same internalization route. In addition, this putative increased recycling has only been described after treating the cells for long time periods with EGF; treatment with ligand for short periods of time results in increased EGFR activation without increased total EGFR number (Pim et al., 1992; Crusius et al., 1998) .
As part of understanding how HPV16 E5 transforms epidermal cells, it is necessary to determine the signi®cance of the binding of this protein to the 16K proteolipid. In this communication we analyse this question. We identify the domain of the viral protein responsible for the binding and show experiments demonstrating that E5 binding to 16K can be dissociated from ligand-mediated, E5-modulated EGFR activation.
Results

Truncated mutants of HPV16 E5HA and HPV16 E5
Hydropatic analysis of the HPV16 E5 protein reveals the existence of three well de®ned hydrophobic regions, of which the ®rst one is the longest (Figure 1 ). To determine the region of the HPV16 E5 protein responsible for binding to the 16K proteolipid, we constructed four truncated mutants by deleting each time one of the hydrophobic regions. For this, stop codons were introduced at amino acids 30, 36, 54, and 79. Thus, all proteins have the same N-terminus (tagged or not with the HA epitope) and lack dierent regions from the C-terminus (see Figure 1) . Mutant R79 lacks only the last ®ve amino acids while the A54 lacks the complete third hydrophobic domain, and the V36 and R30 contain only the ®rst hydrophobic domain.
We ®rst analysed the truncated forms to determine if they could be inserted into membranes. RNA was prepared and translated in vitro in the presence of microsomes. The microsomes were separated from the translation reaction by centrifugation. As a control, RNA was also prepared from a recombinant DNA that encoded for a C-terminal AU1 tagged form of the 16K proteolipid which is known to insert and assemble in microsomes into complexes (Dunlop et al., 1995) . Polypeptides of the expected size for the full length and truncated forms of HPV16 E5 and 16K proteolipid are present in the microsomal pellet ( Figure 2 , lanes 2, 3, 5, 7, 9 and 11). The wild-type and truncated forms of HPV16 E5 are therefore capable of associating with membranes.
When equal amounts of RNA encoding for wt/ mutants of the E5HA and the 16KAU1 proteolipid were translated separately or together in the presence of microsomes, the amount of the respective protein species in the microsomal fraction present is similar (Figure 2, lanes 4, 6, 8, 10, and 12) showing that cotranslation of both RNAs does not aect their relative translational capacity.
Analysis of the binding HPV 16 E5HA and mutants to the 16KAU1 proteolipid
Binding of HPV16 E5HA proteins to 16KAU1 was analysed by immunoprecipitation from solubilized microsomal fractions using monoclonal antibodies to the HA and AU1 epitopes. Equal amounts of RNA encoding the test proteins were translated together or separately in the presence of the microsomes. The microsomes were pelleted before solubilization in RIPA buer and, in the case of the separate translation experiments, equal amounts of the solubilized mem- S-(Met+Cys). The microsomes were pelleted free of the in vitro translation mix and the products were analysed in 15% SDS ± PAGE before exposing to a ®lm. Molecular weight markers in kDa are shown on the right branes were mixed. All solubilized membranes were then divided into two aliquots for immunoprecipitation by either HA or AU1 monoclonal antibodies. The immunoprecipitates were then analysed by SDS ± PAGE (Figure 3a) .
Only when full length HPV16 E5HA and the 16KAU1 proteolipid are synthesized in the same reaction mix is a complex formed between the two. This complex can be precipitated by either HA or AU1 antibodies (Figure 3b, lanes 3 and 4) . There is no complex present if the two are translated separately suggesting binding is dependent upon insertion into the same microsomal membranes (Figure 3b, lanes 1 and  2) . There is similar level of complex formation between the R79 mutant in the co-translation (Figure 3b, lanes  19 and 20) , but the other truncated forms of HPV16 E5HA show little binding (Figure 3b, lanes 7, 8, 11, 12, 15, and 16) . These results suggest that the binding region of the HPV16 E5 protein to the 16K proteolipid resides between amino acids 54 and 78 of the former.
We further analysed the binding characteristics of mutants Y63F-Y68F, H75N, H77Q, and H75F-H78Q to 16K proteolipid using the same approach. As shown in Figure 3c , all mutants were able to bind to the 16K proteolipid with the same eciency as the wt, suggesting that these residues are not involved in binding of E5 to the H + ATPase subunit.
EGFR activation in HPV16 E5 wt and mutant forms in human keratinocytes (HaCaT cells)
We sought next to analyse the eect of the dierent E5 mutants on activation of the EGFR in transfected HaCaT cells, a cell line derived from human keratinocytes. It has already been shown that in these cells expression of HPV16 E5 results in an increased activation of the EGFR in the presence of ligand, without concomitant increase in the total number of receptors (Pim et al., 1992; Crusius et al., 1998) . Permanent transfectants of HaCaT cells with HPV16 E5 and the dierent mutants were prepared and to avoid clonal variations in the analysis, we used a polyclone comprising more than 50 isolated clones for each transfection. We used both HA tagged and nontagged forms of HPV16 E5 and found no dierence between the two forms in subsequent studies. PCR analysis of DNA extracted from the pooled clones showed the presence of the HPV16 E5 gene ( Figure  4a ). The expression of RNA corresponding to the genes was examined by RT ± PCR (Figure 4b ). RNA was isolated from the polyclones and RT ± PCR was performed using primers corresponding to the 5' and 3' ends of the E5 sequence. The results of the PCR reactions demonstrate that all clones produce speci®c RNA for HPV16 E5 and mutant forms. 2, 5, 6, 9, 10, 13, 14, 17, and 18 are co-immunoprecipitations with both products translated separately. Lanes 3, 4, 7, 8, 11, 12, 15, 16, 19, and 20 The activation of the EGFR was analysed in the polyclones as described before (Crusius et al., 1998) . Transfected polyclones were serum-starved for 24 h and treated with EGF for 5 min and, under these conditions, E5 expression results in an increased EGFR activation (Pim et al., 1992; Crusius et al., 1998) . In a ®rst series of experiments, transfectants containing the HPV16 E5HA (wt) were treated with EGF and the EGFR activation was analysed by immuno¯uorescence using an antibody speci®c for the activated receptor. A clear overactivation of the EGFR was observed, indicating that the presence of an epitope at the N-terminus of the E5 proteins does not change its biological eect on EGFR activation (results not shown).
This overactivation was con®rmed by immunoblotting with an antibody speci®c to the activated EGFR (Figure 5a) . Analysis of the polyclones transfected with truncated forms of HPV16 E5, including R79, showed that EGFR was not superactivated and the level of EGFR activation was the same as that in the control polyclone transfected with the empty vector, pCl-Neo. However, as found previously (Straight et al., 1993) there was superactivation by the full length E5 (approximately 2.5-fold by quantitative scanning of the immunoblots).
Finally, transfectants produced with the point mutants described above showed the same enhanced EGFR activation as the wild type (data not shown), demonstrating that the mutated amino acids were not involved in the E5-mediated modulation of the EGFR.
Discussion
Our results show that HPV16 E5 binds in vitro to the 16K proteolipid (subunit c) of the V-ATPase and this binding is dependent on the presence of microsomal membranes in the translation system. The fact that coprecipitation of E5 and 16K only occurs when using co-translated proteins suggests that both proteins must be spatially related in the same membrane.
The deletions used in our study demonstrate that the hydrophobic region between amino acids 54 and 78 of the E5 protein is necessary for binding to the 16K proteolipid. This suggests the nature of binding is through hydrophobic interactions, but even so is speci®c as the N-terminal hydrophobic regions of HPV16 E5 (i.e. mutants R30, V36, and A54) do not bind. Our study, taken together with similar mutational studies (Goldstein et al., 1992a,b; Andresson et al., 1995; Ashra® et al., 2000) on BPV1 E5 and BPV4 E8, a structural and functional homologue of BPV1 E5, lead to the conclusion that this family of papillomaviral proteins all bind to the 16K proteolipid within transmembrane domains. There may be dierences in the nature of the interaction as BPV1 E5 is thought to bind to the 16K proteolipid primarily via residue Q17 by a polar interaction with a strictly conserved glutamic acid on the fourth transmembrane a-helix of the 16K proteolipid (Goldstein et al., 1992b) , whereas as binding of HPV16 E5 and BPV4 E8 appears to be independent of such an interaction.
As well as understanding how HPV16 E5 binds to the 16K proteolipid, it is important to determine the functional signi®cance of this binding, particularly in relation to receptor activation and transforming activity by HPV16 E5. Although the full biological activity of the HPV16 E5 protein is not known, it is clear that a major activity is ligand-dependent modulation of the EGFR (Leechanachai et al., 1992; Pim et al., 1992; Straight et al., 1993; Crusius et al., 1998) . It has been postulated that this eect is mediated by binding of E5 to the 16K proteolipid located at the endosomal membranes which may disturb V-ATPase function . Indeed, it has been shown that expression of HPV16 E5 in keratinocytes delays the normal decrease in acidi®cation of early endosomes (Straight et al., 1995) . This disturbance might result in increased EGFR recycling and thence increased signalling to the cell nucleus (Leechanachai et al., 1992; Pim et al., 1992; Straight et al., 1993) . Increased receptor cycling is also thought to partly explain the transforming eects of BPV1 E5. However, the data from our study dissociates the binding of HPV16 E5 to the 16K proteolipid from EGFR activation. Full length HPV16 E5 and R79 both bind the 16K proteolipid equally eciently but only the former is capable of superactivation of EGFR. This could be explained by there being insucient of the mutant proteins in the permanent transfectants, and we cannot exclude it Figure 4 Analysis of the permanent clones in HaCaT cells. (a) Genomic DNA was extracted from HaCaT cells stably transfected with pCl, E5, and the four mutants (R30, V36, A54, and R79), and used as template in a PCR performed with oligos corresponding to the T7 and T3 promoters. (b) Total RNA was extracted from the same clones and used to perform RT and posterior PCR with a pair of oligos corresponding to the 5' and 3' ends of the DNA encoding E5 (Bubb et al., 1988) . In both panels, the plasmid pCl-Neo E5 was used as a positive control (C+). Standard sizes are in bp on the right Figure 5 Ligand-mediated overactivation of EGFR in HaCaT-E5 cells. Western blots were made with total protein extracts from pCl, E5, R30, V36, A54, and R79 HaCaT cells serum starved for 24 h and then treated with 25 ng/ml of EGF for 5 min. (a) Antiactive EGFR; (b) anti-total EGFR because of the diculty in detecting E5 proteins by immunoblotting in permanent transfected cells. However, it seems unlikely for three reasons. Firstly, when wt and mutant E5 genes were transiently transfected in cells, we always observed a similar amount of tagged E5 proteins by immunoblotting (our unpublished results). Secondly, we have previously found (Oelze et al., 1995) in permanently transfected cells that a limited amount of wt E5 RNA was sucient to produce enough E5 protein to upregulated ligand-mediated EGFR activation, and thirdly, the observations in this present study came from pooling of 50 transfectants to overcome clonal variations in expression.
Thus, we can conclude that EGFR activation by HPV16 E5 is working through a V-ATPase independent route. This conclusion is supported by a number of other indirect experimental observations. For example, endosomes acidi®cation by chloroquine did not result in increased receptor recycling (Straight et al., 1995) . Endosomal acidi®cation is also not expected to be required for EGFR activation by transforming growth factor-a (TGF-a), an EGFR ligand that is less dependent on endosomal acidi®cation for separation from the receptor, in HPV16 E5 expressing cells. Likewise, short-term treatment of E5-expressing cells with EGF results in an increased EGFR activation without increased number of receptors, suggesting that receptor recycling is not involved in the regulation of receptor activation (Pim et al., 1992; Crusius et al., 1998) . Our observation with HPV16 E5 ties in with a recent study on BPV4 E8. Here the transforming activity of BPV4 E8 has also been found to be independent of binding to the 16K proteolipid (Ashra® et al., 2000) .
If EGFR activation by HPV16 E5 is not working through the binding to the 16K proteolipid, how might this process operate. One possibility is that the HPV16 E5 binds directly to the receptor and there is experimental evidence showing just this, although contradictory results have been reported (Conrad et al., 1993; Hwang et al., 1995) . A similar situation may also be the case for BPV1 E5 which is known to bind to the PDGFR, and indeed heterotrimeric complexes can be formed between BPV1 E5, 16K proteolipid and PDGFR (Goldstein et al., 1992a) . Nevertheless, in contrast with BPV1, HPV16 E5 modulates receptors only in the presence of ligand, suggesting a dierent molecular mechanism than that for BPV1 E5 (Martin et al., 1989) . Interestingly, the eect of HPV16 E5 on receptor modulation seems to be speci®c for EGFR, since addition of PDGF to HPV16 E5-transfected ®broblasts shows no eect on cell proliferation (Leechanachai et al., 1992) .
Our data show that binding of HPV16 E5 to the 16K proteolipid is not part of the mechanism of EGFR activation and, therefore, the functional signi®cance of this interaction may be dierent from what was ®rst hypothesized on the discovery of the interaction between these transforming viral proteins and a subunit of the V-ATPase (Straight et al., 1995; Finbow et al., 1991) . The 16K proteolipid binds to a number of other proteins including other components of the VATPase (Finbow and Harrison, 1997; Dunlop et al., 1995) and b1 integrin receptors (Skinner and Wildeman, 1999) . A possibility is that the binding between these two proteins provides a mechanism for distributing HPV16 E5 (and perhaps other papillomaviral E5 proteins) to speci®c targets within the cell membrane.
Materials and methods
Construction of HPV16 E5HA and E5 mutants
The plasmid pCl-Neo (Promega) was used to generate E5 wild type (wt) and mutant clones. Two series of recombinants were produced, one carrying the E5 wt or the corresponding mutations cloned immediately after the cytomegalovirus promoter region, and another series carrying the hemagglutinin (HA) epitope YPYDVPDYA cloned at the N-terminus of the viral protein. Deletions at amino acids 30, 36, 54, and 79 of the sequence were produced by introducing double stop codons at these positions using the Quick Change SiteDirected Mutagenesis System (Stratagene). Point mutations Y63F, Y68F, H75N, and H77Q, as well as combinations of them were produced with the same system. Point mutants and deletions were veri®ed by sequencing.
Cell lines
HaCaT cells, a spontaneously immortalized human keratinocyte cell line (provided by Dr N Fusenig), were transfected with DNA of the wt and the dierent mutants using the poly-L-ornithine method (Neal and McCance, 1995) . Stable transfectants were selected with G-418 (1000 mg/ml) for 14 days. The presence of E5 DNA in the cells was detected by genomic PCR analysis with oligos corresponding to the T7 and T3 sequences¯anking the E5 gene in the plasmid. PCR products were sequenced to ensure that the desired mutations were conserved in the selected transfectants. Individual clones of each transfection were pooled together to produce a polyclone, used for all analysis described here. The corresponding mRNAs were detected by reverse transcription and PCR using oligos corresponding to the 5' and 3' ends of the E5 gene (Bubb et al., 1988) . HaCaT cells transfected with the vector pCl-Neo alone were used as controls. Cells were maintained in DMEM-Glutamax (GIBCO) supplemented with 10% FCS and penicillin/streptomycin.
In vitro transcription and translation
For the in vitro transcription of the dierent species of HPV16 E5HA (wt and mutants, cloned in the pCl-Neo vector), and the 16K proteolipid from Nephrops norvegicus [Norway lobster; 85% identity to the 16K proteolipid of human (Hasebe et al., 1992) ; cloned in the pYES2 vector from Invitrogen and tagged with the AU1 epitope at the Cterminus], we used 1 mg of each plasmid and the T7 MEGA Shortscript Kit (Ambion) as described (Faccini et al., 1996) . Equivalent amounts of RNA (wt and mutants) were cotranslated with 16KAU1 RNA in the presence of canine pancreatic microsomes (Promega) and 35 S-(Met+Cys) (Amersham), as was previously described (Faccini et al., 1996) . In addition, each mRNA was translated separately using the same conditions.
Immunoprecipitations
Half of each in vitro co-translation product was immunoprecipitated with 3 ml of a mouse monoclonal antibody anti-AU1 (Babco) and the other half with 5 ml of a rat monoclonal antibody anti-HA (Boehringer). The same immunoprecipitations were carried out with the products obtained separately, mixing equivalent amounts of each product. After incubation overnight at 48C, protein GSepharose was added for 1 h at room temperature. Following three washes in RIPA buer [20 mM MOPS, pH 7.5/150 mM NaCl/1 mM EDTA/0.5% Triton X-100/0.5% (wt/vol) sodium deoxycholate/0.1% SDS/1 mg/ml aprotinin], Sepharose beads were resuspended in 20 ml of SDS loading buer, heated at 1008C for 2 min, and then separated by 15% SDS ± PAGE. The gels were then dried and exposed to a ®lm.
Activation of EGFR and immunoblotting
Subcon¯uent transfected HaCaT cells (70 ± 80%) were incubated for 24 h in serum free DMEM, and then harvested for protein or pulsed for 5 min with EGF (25 ng/ml) to activate their receptors, lysed in 1% SDS, heated for 3 min at 908C, and sonicated. Protein concentrations of the lysates were determined by using the Bio-Rad Detergent-Compatible Protein Assay and 50 mg of the total protein extracts were resolved in 7.5% SDS ± PAGE. Activation of the EGFR was demonstrated by immunoblotting with an antibody to the activated form of EGFR (Transduction Laboratories). After stripping the blot, a polyclonal anti-total EGFR (Santa Cruz) was used to check for the total amount of the receptor. Detection was performed by using enhanced chemiluminescence (ECL, Amersham). The experiments were repeated four times to ensure reproducibility.
